The iconic rise of Viagra has firmly established as a benchmark of pharmaceutical success, yet its position within the broader market now raises questions about potential yields . Copycat versions are undercutting market share, leading to anxieties that investing in companies significantly dependent to Viagra's former influence could be a dangerous